Sonic Incytes Introduces VelacurTM at 2021 Digital Medicine & MedTech Showcase
|Vancouver, Canada, January 6, 2021 – Sonic Incytes Medical Corp. is pleased to present its breakthrough liver health assessment solution, Velacur™, at the Digital Medicine & Medtech Showcase 2021, part of Biotech Showcase™ 2021 and during the 39th Annual JP Morgan Healthcare Conference, taking place the second week of January.|
Affecting 100 million Americans by 2030, and millions more around the world, chronic liver disease is an emerging global health crisis. With the US commercial launch of Velacur™ in 2021, there is now a practical way to assess millions of people before the onset of advanced liver disease.
“Healthcare practitioners are currently not well equipped to manage this disease because existing diagnostic tools are either expensive, inefficient, inaccessible or inaccurate,” states George Aliphtiras, CEO of Sonic Incytes. “Velacur™ is the first handheld 3D liver health assessment tool that enables an early and accurate diagnosis, preventing and reversing disease.”
Digital Medicine & Medtech Showcase is an investor conference focused on providing the very latest in digital medicine, medtech innovations, and cutting-edge technologies. It helps drive advances by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities.
“We are delighted that Sonic Incytes will be presenting at Digital Medicine & Medtech Showcase this year,” said Sara Demy, CEO of Demy-Colton. “Digital Medicine & Medtech Showcase is a prime occasion for digital medicine and medtech entrepreneurs and investors to come together to discover the potential of innovative technologies that will drive the future of drug discovery and healthcare.”
ABOUT SONIC INCYTESSonic Incytes believes in creating accessible and affordable diagnostic solutions – with health insights you can count on – to improve patient care. Recognizing the rise of chronic liver disease, Sonic Incytes has made it its mission to reduce the disease by enabling routine assessment and improved management of liver health. Its breakthrough, point of care ultrasound solution, Velacur™, is redefining the standard of care in quantifying chronic liver disease – with diagnostic accuracy comparable to MRI. Founded in 2017, Sonic Incytes is a health technology company headquartered in Vancouver, British Columbia, Canada. Follow us on LinkedIn, Twitter, YouTube and www.sonicincytes.com.
For more information, please contact firstname.lastname@example.org.